A phase III, randomized, placebo-controlled trial of adjuvant nivolumab plus ipilimumab in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after radical or partial nephrectomy (CheckMate 914) Meeting Abstract
| Authors: | Bex, A.; Grünwald, V.; Russo, P.; Tomita, Y.; Berghorn, E.; McHenry, M. B.; Motzer, R. J. |
| Abstract Title: | A phase III, randomized, placebo-controlled trial of adjuvant nivolumab plus ipilimumab in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after radical or partial nephrectomy (CheckMate 914) |
| Meeting Title: | 43rd ESMO Congress (ESMO 2018) |
| Journal Title: | Annals of Oncology |
| Volume: | 29 |
| Issue: | Suppl. 8 |
| Meeting Dates: | 2018 Oct 19-23 |
| Meeting Location: | Munich, Germany |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2018-10-01 |
| Start Page: | mdy283.136 |
| Language: | English |
| ACCESSION: | WOS:000459277302110 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdy283.136 |
| Notes: | Meeting Abstract: 927TiP -- Appears on page viii330 of the abstract book -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
